Non-communicable Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
J Epidemiol Community Health. 2010 Jul;64(7):604-9. doi: 10.1136/jech.2008.086207. Epub 2009 Aug 24.
Children with Down's syndrome (DS) who developed leukaemia have had a worse prognosis than other children with leukaemia in the past. In the 1970s and early 1980s, some children with DS who developed leukaemia received fewer cycles of chemotherapy or were advised not to have treatment.
In this population-based study, trends in 5-year survival from leukaemia were evaluated for children with and without DS who were diagnosed in Great Britain during 1971-2000 and followed to the end of 2004.
For all children, with and without DS, survival has increased dramatically over the 30 year study period. For lymphoid leukaemia, survival in children with DS increased, but remains lower than for other children (5-year survival 59% vs 83% during 1996-2000). For acute non-lymphoblastic leukaemia (ANLL), however, 5-year survival improved substantially for children with DS, from less than 1% in the early 1970s to over 80% in the 1990s. For other children, survival increased from 6% to 64% during the same period.
Survival for all children diagnosed with leukaemia has improved during the last three decades. For lymphoid leukaemia, the inferior outcome observed on more recent treatment protocols in children with DS remains an area for concern. For ANLL, the improvement in survival for children with DS is due to a number of factors, namely increased recruitment of these children to clinical trials, changes in clinical practice and important differences in the biology of myeloid leukaemia in young children with DS, resulting in a better response to some chemotherapeutic agents.
过去,唐氏综合征(DS)患儿白血病的预后比其他白血病患儿差。在 20 世纪 70 年代和 80 年代早期,一些患有 DS 的白血病患儿接受的化疗周期较少,或被建议不进行治疗。
在这项基于人群的研究中,评估了 1971 年至 2000 年期间在英国诊断为白血病且在 2004 年底前接受随访的有无 DS 的患儿的白血病 5 年生存率的趋势。
在 30 年的研究期间,所有患儿(有无 DS)的生存率均显著提高。对于淋巴细胞白血病,DS 患儿的生存率有所提高,但仍低于其他患儿(1996-2000 年 5 年生存率分别为 59%和 83%)。然而,对于急性非淋巴细胞白血病(ANLL),DS 患儿的 5 年生存率在过去 30 年中大幅提高,从 20 世纪 70 年代早期的不足 1%提高到 90 年代的 80%以上。在同一时期,其他患儿的生存率从 6%提高到 64%。
在过去的 30 年中,所有被诊断患有白血病的患儿的生存率都有所提高。对于淋巴细胞白血病,DS 患儿在最近的治疗方案中观察到的较差结果仍然令人担忧。对于 ANLL,DS 患儿生存率的提高归因于多个因素,即更多地招募这些患儿参加临床试验、临床实践的改变以及 DS 年幼患儿髓性白血病生物学的重要差异,从而对一些化疗药物产生更好的反应。